WARREN LEE STARKEBAUM
Pilots at Trenton Ln, Minneapolis, MN

2007009, May 3, 2007

Oct 28, 2005

11/261407

Yelena Tropsha - Plymouth MN, US
Warren Starkebaum - Plymouth MN, US

A61K 38/17, A61F 2/02

424423000, 514002000

Method and article for restoring function to a region of a body selected from the group consisting of a gastrointestinal tract and a urinary tract of a patient. A biological agent is optionally associated with a carrier and inserted into the region of the body. The biological agent is stabilized in the region of the body. The biological agent is selected from a group consisting of nerve cells, interstitial cells of Cajal, stem cells and combinations thereof.

7043295, May 9, 2006

Apr 26, 2002

10/133251

Warren L. Starkebaum - Plymouth MN, US

Medtronic, Inc. - Minneapolis MN

A61B 5/04, A61K 9/22, A61M 31/00

600546, 6048911, 604503, 604 66, 604 67, 607 40

Methods and systems for treating patients suffering from eating disorders, e. g. obesity, through the dispensation of a drug by an implantable infusion pump (IIP) delivering drug into the cerebral spinal fluid (CSF) at a site of the intrathecal space in amounts and at times effective to suppress the patient's appetite through interaction of the drug transported through the CSF with receptors in the brain. Delivery of a programmed drug dosage is preferably by one of time-out of programmed time(s) of day, a command received from the patient, or a trigger signal developed from a sensed GI tract signal accompanying peristalsis.

7580751, Aug 25, 2009

Apr 29, 2005

11/118629

Warren L. Starkebaum - Plymouth MN, US

Medtronic, Inc. - Minneapolis MN

A61N 1/18

607 40

A stimulation device for electrical stimulation of a target location of a gastrointestinal tract of a patient that includes a device housing sized for introduction into a gastrointestinal tract, wherein the device housing is configured to attach to a connector, an electrical pulse generator, mounted within the device housing, to generate an electrical stimulation waveform, one or more electrodes electrically coupled to the electrical pulse generator and mounted to the device housing to deliver the electrical stimulation waveform to the gastrointestinal tract, and a fixation structure to attach the device housing to the target location of the gastrointestinal tract, wherein the stimulation device is configured to be tethered to an area around the target location using the connector. A method for attaching a stimulation device of the invention to a wall of a gastrointestinal tract is also included.

2006009, May 4, 2006

Oct 29, 2004

10/977338

Warren Starkebaum - Plymouth MN, US

A61F 13/00

424422000

In general, the invention is directed to devices and methods for destroying targeted body tissue. A hydrogel implant, configured to be implanted in a target tissue, includes an associated chemical agent, such as a proteolytic chemical agent. When implanted in the targeted tissue, the implant expands and discharges the chemical agent, destroying the target tissue. Because the chemical agent is associated with the hydrogel implant, and because the hydrogel implant is less likely to move from its site of implantation, there is reduced risk that the chemical agent will migrate and adversely affect non-targeted tissues.

2012027, Nov 1, 2012

Jan 27, 2012

13/360429

Warren L. Starkebaum - Plymouth MN, US
Orhan Soykan - Shoreview MN, US
Daniel Bloomberg - Minneapolis MN, US

Medtronic, Inc. - Minneapolis MN

A61N 1/36, A61B 5/053

600547, 607 40

In some examples, the disclosure relates to a systems, devices, and techniques for monitoring the occurrence of food intake by a patient. In one example, the disclosure relates to a method including determining a phase of tissue impedance at one or more gastrointestinal tract locations of a patient via a medical device, and determining the occurrence of food intake by the patient based on the determined phase of the tissue impedance. In some examples, a medical device may control the delivery of therapy to a patient based on the determination of food intake based on the phase to the tissue impedance.

2004021, Oct 28, 2004

Apr 25, 2003

10/424010

Warren Starkebaum - Plymouth MN, US
Thomas Prentice - Lake Elmo MN, US

Medtronic, Inc. - Minneapolis MN

A61B018/18

606/032000, 606/041000

The invention provides methods and devices for ablation of stomach tissue to treat obesity. For example, the invention may involve ablation of mucosal tissue to inhibit ghrelin production, recognized as a root cause of increased appetite. The invention alternatively may involve ablation of sub-mucosal tissue to alter myoelectric activity and thereby induce gastroparesis. As a further alternative, gastric muscle tissue, vagal nerves within the stomach or the pyloric region may be ablated to alter stomach function and thereby induce gastroparesis.

2004019, Sep 30, 2004

May 19, 2003

10/441775

Warren Starkebaum - Plymouth MN, US
David Dinsmoor - St. Paul MN, US

Medtronic, Inc. - Minneapolis MN

A61N001/18

607/040000

A system and method for treating gastro-esophageal reflux disease (GERD) in a patient are disclosed. Electrical stimulation pulses are generated by an implantable neurostimulator and delivered to a portion of a patient's stomach located downstream from the lower esophageal sphincter via an implantable medical electrical lead.

8135470, Mar 13, 2012

Jun 2, 2009

12/476893

John G. Keimel - North Oaks MN, US
Warren L. Starkebaum - Plymouth MN, US
Gary L. Lubben - Independence MN, US

Medtronic, Inc. - Minneapolis MN

A61N 1/36

607 40, 607133

Techniques are described that allow an implantable device to sense gastric data and activity data from a patient, and estimate the patient's amount of energy consumed and energy expended based on the sensed data. A system provides feedback to the patient, a family member, or a doctor about the patient's energy consumed, energy expended, and net energy. The data may be provided in table or graphical format, and may show daily or weekly energy balance data or may show a trend of the daily or weekly energy data. The patient may receive feedback by an implanted alert module that provides and audio alert or a vibration alert. In addition, data acquired by the system may be used to adjust the patient's stimulation therapy parameters.

2005024, Nov 3, 2005

Apr 30, 2004

10/837074

Warren Starkebaum - Plymouth MN, US

Medtronic, Inc. - Minneapolis MN

A61F002/04

623023640, 606157000

Medical devices and methods for treatment for obesity forming a partial obstruction in the esophagus to limit food intake. The partial obstruction limits the rate of food intake by a patient, discouraging the patient from quickly consuming an excessive amount of food at one time. In particular, the partial obstruction physically restricts the passage of food, and can cause patient discomfort when an excessive amount of food is consumed.

2006026, Nov 23, 2006

Apr 24, 2006

11/379911

Timothy Herbert - Maple Grove MN, US
Warren Starkebaum - Plymouth MN, US

Medtronic, Inc. - Minneapolis MN

A61N 1/36

607040000

An intra-luminal device for gastrointestinal electrical stimulation is self-powered and self-contained within a capsule-like housing, and is capable of non-surgical implantation within the patient. The device includes an implantable pulse generator and one or more electrodes mounted within a common device housing. The device housing is capable of endoscopic introduction to a desired location within the gastrointestinal tract, such as the stomach, via the esophagus. The device may be appropriate for short-term, mid-term or trial stimulation applications.